Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer

by Rottenfusser Andrea, Mader Robert M, Rudas Margaretha, Gampenrieder Simon P, Bago-Horvath Zsuzsanna, Dubsky Peter, Pluschnig Ursula, De Vries Catharina, Bartsch Rupert, Wiltschke Christoph, Gnant Michael, Zielinski Christoph C, Steger Guenther G
Published 2009-10-01